Sign in
CLSDQ Stock Price, Chart, Stats & News
Clearside Biomedical, Inc.
Save
Clearside Biomedical, Inc. (CLSDQ) does not currently pay a dividend.
1.30M
Market cap
–
Current P/E
–
Forward P/E
CLSDQ chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Clearside Biomedical, Inc. operates as a biopharmaceutical company, specializing in novel approaches to administer therapies to the posterior region of the eye via the suprachoroidal space. Its market-approved product, XIPERE, is an injectable suspension containing triamcinolone acetonide, utilized to manage macular edema associated with uveitis. Additionally, the firm is progressing CLS-AX, an axitinib injectable suspension intended for suprachoroidal injection, having concluded its Phase 2 clinical trial for the treatment of wet age-related macular degeneration (AMD).
Similar securities
Based on sector and market capitalization
Report issue